- Action
- On January 14, 2025 URGENT MEDICAL DEVICE CORRECTION letters were sent to customers. 4. Actions that should be taken by the customer / user in order to prevent risks for patients or users
" Circulate this Urgent Medical Device Correction letter to all users of the system so that they are
aware of the issue.
" Follow the additional instructions on the use of the mattress included in Appendix B. These
instructions include information for the transfer of the patient and the correct use and
positioning of the mattress.
The information of this Appendix is being included in an Addendum to the Instructions for Use.
Additionally, Philips is creating a Quick Reference Card. The Addendum and the Quick Reference
Card will be available as from end of March 2025. Please refer to Appendix C on how to download
the Addendum to the Instructions for Use and the Quick Reference Card.
" In case that the affected system has been transferred to another organization, please send a
copy of this Urgent Medical Device Correction letter to that organization and inform Philips
about this transfer through the email account: IGT_Recalls@philips.com
" Please complete and return the Response form attached to Philips promptly and no later than
30 days from receipt. Completing this form confirms receipt of the Urgent Medical Device
Correction letter and understanding of the issue and required actions to be taken.
" Should you experience the issue reported in this letter, please report the event to Philips
through your local Philips representative (1- 800-722-9377).
5. Actions planned by Philips Image Guided Therapy Systems to correct the problem
Philips is informing customers of this issue through this Urgent Medical Device Correction.
Additionally, Philips is releasing an Addendum to the Instructions for Use and a Quick Reference Card
that will be available for customers at the end of March 2025.
This Urgent Medical Device Correction letter has been reported to the appropriate Regulatory Agencies.
- Initiated
- 2025-01-13
- Root cause
- Under Investigation by firm
- Distribution
- Worldiwde distribution - US Nationwide and the countries of Afghanistan, Albania, Algeria, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Cambodia, Cayman Islands, Chile, China, Colombia, Costa Rica, C¿te D'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Ethiopia, Fiji, Finland, France, French Polynesia, Georgia, Germany, Ghana, Gibraltar, Greece, Guadeloupe, Guatemala, Guinea, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, JAMAICA, Japan, Jordan, Kazakhstan, Kenya, Korea, Republic of, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Libya, Lithuania, Macao, Macedonia, Malaysia, Maldives, Malta, Martinique, Mauritania, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Nepal, Netherlands, New Caledonia, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, R¿union, Romania, Russian Federation, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sudan, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Tanzania, Thailand, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Uzbekistan, Venezuela, Viet Nam, Yemen.
- Recall number
- Z-1156-2025
- Recall status
- Open, Classified
- CDRH record ID
- 212104
- FDA classified
- 2025-02-20
- Recall event number
- 96132